Experiences with
Obinutuzumab358 public posts
Follicular Lymphoma Patient Survey
Lymphoma Canada is preparing a submission for the panCanadian Oncology Drug Review (pCODR) for:
Obinituzumab in combination with chemotherapy, followed by obinutuzumab maintenance, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab containing
Dr. Castro on HDMP+ Obinutuzumab
Januario Castro out of UCSD where we discussed the results of his trial studying HDMP + obinutuzumab in both untreated and relapsed refractory CLL.
Want to take advantage of all our features? Just log in!
or
Development of infusion-related reactions in patients with CLL treated with obinutuzumab
This paper looks to try and understand infusion reactions from Gazyvaro (obinutuzumab)... study is on going...
We mightn’t like it, but there are ethical reasons to use animals in medical research
(For some history on the development of Rituximab and its fully human protein replacement Obinutuzumab or Gazyva, read Dr Brian Koffman's blog regarding his interview with Dr Jennifer Brown at ASH 2013:
http://bkoffman.blogspot.com.au/2014/02/ash-2013-dr-jennifer-brown-discusses.html )
So the least
ASH 2015: Dr. Jones on combining venetoclax with obinutuzumab, and details about the LRF meeting this weekend and new CLL support groups
We discussed the data for patients with relapsed/refractory CLL on combining the BCL-2 (B-cell lymphoma-2) inhibitor venetoclax with the antibody obinutuzumab, the ongoing European trials and a new study that adds ibrutinib to that mix. You can see a summary and view our interview here.
Integrating Emerging Evidence Into the Management of CLL Patients; what leading CLL experts recommend in 4 case studies
Kipps, MD
The slideset includes consideration of the following treatments plus comparative Progression Free Survival (PFS) and Overall Survival (OS) for many of the new therapies as monotherapies and with mAbs from a range of clinical trials including CLL8 (FCR vs FC), CLL10 (FCR vs BR), CLL11 (Obinutuzumab
Bright future? Only if we keep pushing!
Because drugs such as ibrutinib and idelalisib and obinutuzumab are already approved in many countries and offer pretty spectacular results, pharmaceutical companies may be less willing to invest the billions of dollars it takes to bring a new drug to market.
Explainer: what are biologics and biosimilars?
theconversation.com/explainer-what-are-biologics-and-biosimilars-45308
Thomas Morrow, MD and Linda Hull Felcone explain how biologics differ from chemically derived drugs in ways that affect their cost, production, administration and clinical efficacy here:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564302/
UK - NICE Guidance for NHS England & Wales use of obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
If you have chronic lymphocytic leukaemia, and your doctor thinks that obinutuzumab (with chlorambucil) is the right treatment, you should be able to have the treatment on the NHS.
Obinutuzumab should be available on the NHS within 3 months of the guidance being issued.
UK - NICE Guidance for NHS use of Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia -
[/i]
the other bus arrived today with guidance [TA343] obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia https://healthunlocked.com/cllsupport/posts/131890857/nice-guidance-for-nhs-england-wales-use-of-obinutuzumab-in-combination-with-chlorambucil-for-untreated-chronic-lymphocytic-leukaemia